NO20052265L - Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse - Google Patents

Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse

Info

Publication number
NO20052265L
NO20052265L NO20052265A NO20052265A NO20052265L NO 20052265 L NO20052265 L NO 20052265L NO 20052265 A NO20052265 A NO 20052265A NO 20052265 A NO20052265 A NO 20052265A NO 20052265 L NO20052265 L NO 20052265L
Authority
NO
Norway
Prior art keywords
monoclonal antibody
methods
ligand
ethylenedicycin
tissue
Prior art date
Application number
NO20052265A
Other languages
English (en)
Other versions
NO20052265D0 (no
Inventor
Dong-Fang Yu
David J Yang
Chang-Sok Oh
Jr Jerry L Bryant
Original Assignee
Cell Point Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Point Llc filed Critical Cell Point Llc
Publication of NO20052265D0 publication Critical patent/NO20052265D0/no
Publication of NO20052265L publication Critical patent/NO20052265L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0487—Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

2005 -08- 3 Oppfinnelsen tilveiebringer i generell betydning en ny merkingsstrategi med anvendelse av forbindelser som er N2S2-chelater konjugert til en målsøkingsligand, hvor målsøkingsliganden er. en sykdomscellesyklus-målsøkingsforbindelse, en tumorangiogenese-målsøkingsligand, en tumorapoptose-målsøkingsligand, en sykdomsreseptor-målsøkingsligand, amifostin, angiostatin, monoklonalt antistoff C225, monoklonalt antistoff CD31, monoklonalt antistoff CD40, capecitabin, COX2, deoksycytidin, fulleren, herceptin, humant serumalbumin, laktose, luteiniserende hormon, pyridoksal, kinazolin, talidomid, transferdn eller trimetyllysin. Foreliggende oppfinnelse angår også sett som anvender de aktuelle forbindelser, samt fremgangsmåter for bedømmelse av farmakologien for et aktuelt middel ved anvendelse av foreliggende forbindelser.
NO20052265A 2002-11-07 2005-05-10 Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse NO20052265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42449302P 2002-11-07 2002-11-07
PCT/US2003/036078 WO2004044227A2 (en) 2002-11-07 2003-11-07 Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging

Publications (2)

Publication Number Publication Date
NO20052265D0 NO20052265D0 (no) 2005-05-10
NO20052265L true NO20052265L (no) 2005-08-03

Family

ID=32312817

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052265A NO20052265L (no) 2002-11-07 2005-05-10 Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse

Country Status (12)

Country Link
US (1) US20040166058A1 (no)
EP (2) EP2316493A3 (no)
JP (1) JP2006515835A (no)
KR (1) KR101086690B1 (no)
CN (2) CN1723042B (no)
AU (2) AU2003297261B2 (no)
BR (1) BR0316046A (no)
CA (1) CA2505537A1 (no)
IL (1) IL168376A (no)
NO (1) NO20052265L (no)
PL (1) PL377107A1 (no)
WO (1) WO2004044227A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445826C (en) 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP4680185B2 (ja) 2003-05-30 2011-05-11 パーデュー・リサーチ・ファウンデーション アテローム性動脈硬化症の診断法
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
KR100851272B1 (ko) * 2003-12-22 2008-08-08 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
WO2005087275A2 (en) * 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
EP1827239B1 (en) * 2004-12-23 2019-04-17 Purdue Research Foundation Positron emission tomography imaging method
WO2006074272A2 (en) 2005-01-05 2006-07-13 Board Of Regents, The University Of Texas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
EP1940473A2 (en) 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
US20100104511A1 (en) * 2006-11-22 2010-04-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
CA2677792C (en) 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
GB0804406D0 (en) * 2008-03-10 2008-04-16 Univ Zuerich Metal complexes
KR20100127845A (ko) * 2008-03-24 2010-12-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 심근 질환의 영상-유도된 치료: 조성물, 제조 및 적용
EP2451487A1 (en) * 2009-07-09 2012-05-16 F. Hoffmann-La Roche AG In vivi tumor vasculature imaging
IN2014DN08487A (no) * 2012-03-26 2015-05-08 Univ Texas
KR102124442B1 (ko) * 2018-09-11 2020-06-23 서울대학교산학협력단 황화수소 검출 또는 농도 측정용 조성물 및 이를 유효성분으로 함유하는 생체내 염증, 저산소 손상조직 또는 암의 진단 또는 영상화용 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4558120A (en) * 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4631337A (en) * 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4737550A (en) * 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4871779A (en) * 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
US4694064A (en) * 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4713975A (en) * 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
IN165717B (no) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5279811A (en) * 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US4857599A (en) * 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US5164294A (en) * 1988-05-17 1992-11-17 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5268163A (en) 1990-04-17 1993-12-07 Mallinckrodt Medical, Inc. Method of preparing a radiolabelled technetium complex and kit for performing said method
US5385719A (en) * 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5605671A (en) * 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
US5951964A (en) * 1993-06-04 1999-09-14 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5534241A (en) * 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
DE69536153D1 (de) * 1994-11-17 2011-05-05 Ich Productions Ltd Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JP3737518B2 (ja) * 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US5986074A (en) * 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
CN1265572A (zh) * 1997-04-30 2000-09-06 莱兰斯坦福初级大学评议会 活体内造影细胞死亡的方法
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6284220B1 (en) 1999-06-03 2001-09-04 The General Hospital Corporation Noninvasive imaging of nucleic acid vectors
CN1315554A (zh) 2000-03-24 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶31和编码这种多肽的多核苷酸
EP1296721A2 (en) 2000-04-20 2003-04-02 The University of British Columbia Radiometal complexes of 2-pyrrolylthiones for imaging and therapy
BRPI0111220B8 (pt) * 2000-06-02 2021-07-27 Univ Texas conjugados de fármacos com etilenodicisteína (ec)
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法

Also Published As

Publication number Publication date
IL168376A (en) 2011-06-30
NO20052265D0 (no) 2005-05-10
WO2004044227A2 (en) 2004-05-27
CN1723042A (zh) 2006-01-18
BR0316046A (pt) 2005-09-13
AU2009200201A1 (en) 2009-02-12
EP2316493A3 (en) 2011-08-10
EP1562641A4 (en) 2008-12-03
JP2006515835A (ja) 2006-06-08
AU2009200201B2 (en) 2010-06-24
PL377107A1 (pl) 2006-01-23
EP2316493A2 (en) 2011-05-04
WO2004044227A3 (en) 2004-11-11
KR101086690B1 (ko) 2011-11-25
EP1562641A2 (en) 2005-08-17
CN1723042B (zh) 2010-12-01
KR20050088289A (ko) 2005-09-05
CA2505537A1 (en) 2004-05-27
CN101985443A (zh) 2011-03-16
AU2003297261B2 (en) 2008-10-23
US20040166058A1 (en) 2004-08-26
AU2003297261A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
NO20052265L (no) Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
NO20063539L (no) Anti-glypican 3 antistoff
MY188455A (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
HK1217103A1 (zh) 二芳基乙內酰脲化合物
WO2008141044A3 (en) Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
WO2006034488A3 (en) Cysteine engineered antibodies and conjugates
ATE516842T1 (de) Intravasculärer führungsdraht
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
ATE531390T1 (de) Interleukin-15-(il-15-)spezifische menschliche antikörper
WO2006113432A3 (en) Compounds, compositions and methods
DK1716181T3 (da) CDR-reparerede antistoffer
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
NZ592830A (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
WO2006110745A3 (en) Conjugated anti-psma antibodies
WO2006017759A3 (en) Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2007019541A3 (en) Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
DK1794302T3 (da) Fremgangsmåde til at forøge frøvægt
NZ552372A (en) Propane-1,3-dione derivative or its salt
Saiz et al. Microwave-assisted tandem reactions for the synthesis of 2-hydrazolyl-4-thiazolidinones
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
Kraus et al. A three-component reaction between benzynes, the enolate of acetaldehyde, and unsaturated esters and dihydroisoquinolines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application